Eisai Company Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer.
The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; and Chocola BB plus for the preparation vitamin B2.
It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate.
Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.
Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1941 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10,917 |
| CEO | Haruo Naito |
Contact Details
Address: 4-6-10, Koishikawa Tokyo, 112-8088 Japan | |
| Phone | 81 3 3817 3700 |
| Website | eisai.co.jp |
Stock Details
| Ticker Symbol | ESAIY |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | US28258A1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Haruo Naito | Chief Executive Officer, Representative Corporate Officer and Director |
| Gary Hendler | Senior Vice President and President of EMEA Region |
| Dr. Lynn D. Kramer FAAN, M.D. | Vice President and Chief Clinical Officer |
| Yanhui Feng | Senior Vice President |
| Mitsuru Shomon | Vice President and Chief Financial Officer |
| Keisuke Naito | Representative Corporate Officer, EVice President, Chief Operating Officer and Chief Growth Officer |
| Akiko Nakahama | Vice President of Japan Regulatory Affairs, Manufacturing, Quality and Technology |
| Makoto Hoketsu | Vice President and Chief Information Officer |
| Dr. Katsutoshi Ido | Vice President, Chief Scientific Officer and Head of DHBL Discoverry |
| Terushige Iike | Executive Vice President, Rep. Corporate Officer and Chief IR Officer and Business Officer |